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Abstract 
Background: Artemisinin resistance in Plasmodium falciparum extends across Southeast Asia where it is associated 
with worsening partner drug resistance and a decline in the efficacy of frontline artemisinin-based combination 
therapy. Dihydroartemisinin-piperaquine (DP) is an essential component of preventive and curative treatment in the 
region, but its therapeutic efficacy has fallen in Cambodia.
Methods: A prospective clinical and parasitological evaluation of DP was conducted at two sites in Upper Myanmar 
between August 2013 and December 2014, enrolling 116 patients with acute uncomplicated falciparum malaria. 
Patients received DP orally for 3 days together with primaquine 0.25 mg/kg on admission. Parasite clearance half-lives 
based on 6 hourly blood smears, and day 42 therapeutic responses were assessed as well as parasite K13 genotypes.
Results: Median parasite clearance half-life was prolonged, and clearance half-life was greater than 5 h in 21 % of 
patients. Delayed parasite clearance was significantly associated with mutations in the propeller region of the parasite 
k13 gene. The k13 F446I mutation was found in 25.4 % of infections and was associated with a median clearance half-
life of 4.7 h compared with 2.7 h for infections without k13 mutations (p < 0.001). There were no failures after 42 days 
of follow-up, although 18 % of patients had persistent parasitaemia on day 3.
Conclusion: The dominant k13 mutation observed in Upper Myanmar, F446I, appears to be associated with an 
intermediate rate of parasite clearance compared to other common mutations described elsewhere in the Greater 
Mekong Subregion. Discerning this phenotype requires relatively detailed clearance measurements, highlighting the 
importance of methodology in assessing artemisinin resistance.
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Background
Artemisinin resistance in Plasmodium falciparum is now 
prevalent across much of mainland Southeast Asia [1–6]. 
Resistance is characterized by the clinical phenotype of 
delayed parasite clearance [7, 8] and is associated with 
mutations in the propeller region of the P. falciparum 
kelch13 (k13) gene [6]. This marker has since been vali-
dated extensively in clinical studies and also by labora-
tory transfection [2–4, 9, 10]. Artemisinin resistance is 
clearly associated with ACT failures with reduced clini-
cal efficacy of mefloquine-artesunate reported in Cam-
bodia a decade ago [11, 12]. Four years after adoption of 
dihydroartemisinin-piperaquine (DP) in Cambodia, high 
failure rates were reported, with both artemisinin and 
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piperaquine resistance as contributing factors [13–16]. 
Artemisinin resistance has steadily worsened along the 
Myanmar–Thailand border [17, 18] where the k13 C580Y 
mutation now predominates, and is present in central 
and southern Myanmar where independent mutations 
have emerged [2, 3, 19]. A recent molecular survey of k13 
gene mutations, which obtained data from ten adminis-
trative regions, indicated that artemisinin resistance now 
extends across much of Myanmar [1].
The situation in relatively remote Northern Myanmar 
has been challenging to ascertain. Several clinical stud-
ies have been undertaken at the border between Kachin 
State and Yunnan Province in China [20, 21]; based on a 
combination of day 3 parasite positivity rates and subse-
quent molecular and in vitro studies [4, 5, 22] it has been 
concluded that artemisinin resistance is also present in 
this region.
Dihydroartemisinin-piperaquine is one of three arte-
misinin-based combinations registered in Myanmar, but 
it is not widely used because the main donors support 
distribution of artemether–lumefantrine free of charge 
through the government health system and international 
non-governmental organizations and at a reduced price 
in the private sector; nor was piperaquine monotherapy 
generally available in the past. Consistent with this there 
are no reports in Myanmar of reduced piperaquine sensi-
tivity (in vivo or in vitro). DP is the only currently avail-
able drug for mass treatment in this region [23]. In order 
to investigate the degree and extent of artemisinin resist-
ance in Northern and Central Myanmar, as well as the 
current efficacy of DP, we undertook a two-centre pro-
spective study, using a combined protocol to characterize 
early parasitological responses (i.e. to assess artemisinin 
resistance) and the overall therapeutic efficacy of DP.
Methods
Study design
An open-label single arm clinical trial was conducted in 
two hospitals, one located in Myitkyina, Kachin State 
in Northern Myanmar and the other in Thabeikkyin, 
Mandalay Region in central Myanmar (Additional file 4: 
Figure S1). The two sites are situated in areas of low 
malaria transmission (entomological inoculation rate; 
EIR  <  1) [24]. This trial was registered at ClinicalTrial.
gov (NCT01350856). The Oxford Tropical Research Eth-
ics Committee (UK) (OXTREC reference 06–11) and the 
Defence Services Medical Ethics Committee (Myanmar) 
approved the study protocol.
Study participants
Inclusion criteria were acute uncomplicated P. falci-
parum malaria confirmed by positive blood smear 
on microscopy with asexual forms of P. falciparum 
(including mixed infection with non-falciparum spe-
cies), parasitaemia of between 5000 and 200,000 per 
µL determined on a thin or thick blood film, and fever 
defined as >37.5  °C tympanic temperature or a history 
of fever. Male and non-pregnant female patients aged 
between 6 months and 65 years were recruited; children 
less than 5 years of age were not included at the Thabeik-
kyin site because of the absence of a paediatric special-
ist. Patients (or parents/guardians of minors) provided 
written informed consent to enrol in the study; those 
unable to read or write provided informed consent with 
a witness present. In patients from 10 to 17 years of age 
assent was also obtained. Exclusion criteria were signs of 
severe and/or complicated malaria [25], haematocrit less 
than 25 % or haemoglobin less than 8 g/dL, acute illness 
other than malaria requiring treatment, administration 
of artemisinin derivatives within the previous 7 days, his-
tory of allergy to artemisinins or to dihydroartemisinin-
piperaquine, and previous splenectomy.
Anti‑malarials
Dihydroartemisinin-piperaquine (DP) was purchased as 
Duo-Cotecxin® from Beijing Holley-Cotec Pharmaceu-
ticals. Primaquine (Remedica Pharmaceuticals) was pro-
vided by 3MDG. Patients received DP orally each day for 
3 days, with a target daily dose of 2.4 mg/kg dihydroar-
temisinin and 18  mg/kg piperaquine [25]. All patients 
received primaquine 0.25  mg/kg single dose on day 0 
after the first dose of DP. Dosing was by weight catego-
ries (See Additional file 1). If the patient vomited within 
1/2 h of anti-malarial ingestion, the dose was repeated. If 
vomiting occurred between 1/2 and 1 h, half the dose was 
repeated.
Admission procedures
Patients were admitted to the hospital for at least 3 days 
for supervised treatment and 6 hourly blood smears. Par-
asite densities were estimated by blood smear every 6 h 
up to 48 h and daily thereafter until two negative consec-
utive slides were observed [26]. EDTA whole blood was 
collected at hour 0 and packed red cells stored at −20 °C 
for later k13 gene sequencing and genotyping in case of 
recurrence.
Follow up assessments
Tympanic temperature and haematocrit were measured 
every 6 h at the same time as malaria smears were taken, 
up to 48 h and then every 12 h until discharge from hos-
pital. After patients were discharged from hospital, fol-
low up assessments were performed at days 5, 7, 9, 14, 21 
for malaria blood smear and haematocrit. A dried blood 
spot on Whatman® 3MM cellulose chromatography 
paper was collected on day 7 for piperaquine drug levels. 
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Thereafter, patients were assessed weekly at the clinic and 
blood samples were taken for malaria smear and haema-
tocrit until day 42. Patients unable to come to the clinic 
were visited by research staff at home.
The trial was monitored by the MORU Clinical Trial 
Support Group and data evaluated for compliance 
with the protocol and accuracy in relation to source 
documents.
Microscopy quality control measures and analysis 
of parasite clearance half‑life
Giemsa-stained blood smears were prepared at the study 
sites. Parasitaemia (parasites/µl) was calculated from the 
thin blood film as parasitized red cells per 1000 red blood 
cells  ×  haematocrit  ×  125.6, or the thick film as para-
sitized red cells  ×  8000/number of leucocytes counted 
(usually 200). All blood smears were read by a trained 
laboratory technician and all h0 and h72 slides, plus all 
slides from selected subjects were rechecked by experi-
enced microscopists in the Malaria Laboratory, MORU, 
Bangkok [2].
Molecular studies
Blood samples were processed using standard techniques 
(See Additional file 2). After PCR amplification, the main 
part of the k13 gene (amino acids 210 onwards, includ-
ing the whole propeller region) was sequenced. K13 
sequences for a subset of patients were also incorporated 
into a published country-wide molecular marker survey 
in Myanmar in 2015 [1].
Statistical analysis
Sample size was based on WHO guidelines for single-
arm efficacy studies [27]. A target sample size of 73 
enables detection of a 5 % failure rate with 95 % confi-
dence and 5 % precision for each site. An additional 10 % 
was included to allow for losses to follow up. Based on 
previous studies, this number would also enable distri-
bution of parasite clearance half-lives to be described 
adequately. Data were entered into a web-based data-
base, OpenClinica, version 3.0. Data cleaning and anal-
ysis were done by using STATA statistical software, 
version 13 (StataCorp) and GraphPad Prism software 6.0 
(Graphpad Software Inc.). Parasite clearance half-lives 
were calculated by using the online Parasite Clearance 
Estimator tool from the Worldwide Antimalarial Resist-
ance Network [28].
Fever clearance was defined as the time to the start 
of the first 24-h period during which the temperature 
remained below 37.5  °C. The gametocyte clearance 
time (GCT) was the interval from first detection to last 
detection of gametocytes in a peripheral blood smear. 
Person-gametocyte weeks (PGW) were calculated for 
each case as the number of weeks in which gametocytae-
mia was patent (excluding admission) divided by dura-
tion of follow-up, expressed per 1000 person-weeks. 
Estimated haemoglobin values based on haematocrit 
were used to define anaemia (See Additional file 3).
Continuous variables were presented as mean and 
standard deviation, or if the distribution was non-normal 
as median and interquartile range. Tests of association 
between two categorical variables were performed using 
the Chi squared test, and comparison of non-normally 
distributed continuous variables by Mann–Whitney U 
test.
Simple logistic regression was conducted for associa-
tion between each potential risk factor and prolonged 
parasite clearance half-life, with multiple logistic regres-
sion to analyse resulting risk factors.
Results
The study was conducted between August 2013 and 
December 2014 (See Additional file  4). A total of 3211 
patients were screened and 116 patients enrolled, 44 in 
Myitkyina and 72 in Thabeikkyin (Fig.  1). Two patients 
were found not to meet the inclusion criteria after 
enrolment and were not analysed, leaving a total of 114 
patients in the analysis. The aim was to recruit 80 patients 
per site but recruitment at the Myitkyina site was slower 
than anticipated, possibly owing to regional conflict.
Baseline characteristics
Median patient age was 19 years (IQR 12–25), and males 
accounted for 75  % of all participants (Table  1). Geo-
metric mean (95 % CI) parasite count on admission was 
35,011 (28,613–42,839) parasites/µL with no significant 
difference between sites (p = 0.7). Mixed infection with 
P. vivax was present in 13 (11 %) of the 114 patients. Axil-
lary temperature was >37.5 °C before treatment in a third 
of patients.
Clinical and early parasitological responses
Median (IQR) parasite clearance half-life at Myitkyina 
was 4.4 h (3.4–6.7), significantly longer than Thabeikkyin 
[2.6  h (2.0–3.8, p  <  0.001)] (Fig.  2a). In Myitkyina 39  % 
of patients had parasite clearance half-life more than 5 h 
compared with 13 % in Thabeikkyin (p = 0.001); using a 
4  h cutoff these proportions were 63 and 23  %, respec-
tively (p < 0.001).
Twenty of 114 participants (18  %) remained para-
sitaemic 3  days after treatment [30.2  % of patients in 
Myitkyina and 9.9  % in Thabeikkyin (p  =  0.01)]. Fever 
resolution was rapid (median resolution time was 6 h in 
Myitkyina, 12 h in Thabeikkyin, p = 0.008) (Table 2).
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Curative efficacy
After initial parasite clearance all patients remained para-
site free (including non-falciparum malaria) until 42 days 
(Table  2); two patients were lost to follow-up before 
42 days with negative blood films at their last follow-up 
visit at 7 and 28 days.
K13 sequence and parasitological response
The k13 gene was successfully sequenced in all 114 sam-
ples. The prevalence of propeller (>440) mutations was 
28.9 % (33/114) (Table 3); among these the F446I muta-
tion predominated (29/33, 87.8 %). In Myitkyina 21 of 43 
(49 %) of patients had k13 mutations compared with 12 
Fig. 1 Participant flow chart
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of 71 (16.9 %) in Thabeikkyin. All k13 mutations observed 
had been reported in previous studies. No mutations 
were found in the non-propeller region of k13 (amino 
acids 210–440).
Median parasite clearance half-life was 2.7  h for wild 
type k13 and 4.7 h for F446I mutation (p < 0.001) (Fig. 2b). 
The single cases of propeller mutations P443S, G538V, 
P574L and A676D were associated with half-lives of 6.6, 
4.7, 7.5, and 2.0 h, respectively. The proportion of patients 
still parasite positive at day 3 was higher in infections with 
parasites with k13 mutations (10/33, 30.3 %) compared to 
those with wild type alleles (10/81, 12.3 %) (p = 0.02).
Factors associated with prolonged parasite clearance
For multivariable analyses of factors associated with 
prolonged parasite clearance, half-life cut-off values of 
4 and 5  h were used. With the 4  h cutoff, k13 propel-
ler mutation had an odds ratio of 5.0 (95 % CI 1.9–13.0, 
p = 0.001) while recruitment in Myitkyina had an odds 
ratio of 4.0 (1.7–10.1, p =  0.002). Using a cutoff of 5 h, 
these ratios were 2.3 (95 % CI 0.9–6.1, p = 0.1) and 3.5 
(95 % CI 1.3–9.4, p = 0.01), respectively (Table 4).
Persistent parasitaemia at day 3 was significantly asso-
ciated with site and parasitaemia on admission (using a 
cutoff of 1 %, close to the median) (Table 4); in this mul-
tivariable analysis k13 sequence was not a significant 
factor.
Gametocytaemia
Ten patients (8.8  %) had patent gametocytaemia at the 
time of enrollment, with nine of these recruited in Myit-
kyina (Table 1). The geometric mean (95 % CI) gameto-
cyte density on admission was 83/μL (34–201). Fourteen 
patients (12  %) developed patent gametocytaemia after 
admission. There was no association between gametocyte 
carriage and the presence of k13 propeller mutations 
at the time of enrollment (p =  0.42) or after treatment 
(p =  1.0), suggesting that artemisinin resistance had no 
effect on the proportion of patients with gametocytes at 
or after admission.
The median (IQR) durations of gametocyte carriage 
in Myitkyina and Thabeikkyin were 57 (6–81) and 16.5 
(12–24) h respectively. Overall gametocyte carriage rate 
was 26 PGW per 1000 weeks of follow up. There was no 
association between gametocyte carriage duration and 
geographical location (p  =  0.31), or parasite clearance 
half-life (p  =  0.25). All patients with gametocytaemia 
cleared gametocytes within 96 h from the time gameto-
cytes were first seen.
Haematological changes
One third of participants (35 %) were anaemic on enrol-
ment. The nadir in mean haematocrit occurred on day 
3, after which haematocrit values gradually increased 
(Fig. 3; See Additional file 3). There were no clinically sig-
nificant falls in haemoglobin, or haemoglobinuria. By day 
28, most of the participants’ haematocrit values exceeded 
baseline measurements (Fig. 3).
Safety and tolerance
The median dose (IQR) received by patients for dihy-
droartemisinin, piperaquine and primaquine were 2.2 
(2.1–2.3), 17.5 (16.6–18.5) and 0.26 (0.24–0.28) mg/kg 
respectively. Study medications were generally well toler-
ated although six patients vomited the day 0 medication, 
and one vomited on day 2; all were retreated according to 
protocol. One serious adverse event was reported at the 
Myitkyina site; one patient who had already missed fol-
low-up visits died in a road traffic accident approximately 
2 weeks after the last visit.
Table 1 Baseline characteristics of the patients by study site
Data are presented as median (IQR) unless otherwise indicated
Study site Total Myitkyina Thabeikkyin
Number of patients 114 43 71
Gender (male sex) n (%) 86 (75.4 %) 40 (93.0 %) 46 (64.8 %)
Age year 19 (12–25) 23 (19–29) 13 (11–21)
Weight kg 45 (30–54) 54 (45–56) 34 (23–50)
Height m 1.57 (1.36–1.63) 1.63 (1.6–1.65) 1.47 (1.3–1.58)
BMI kg/m2 18.3 (15.2–20.5) 20.5 (18.4–21.6) 16.3 (14.3–19.5)
Parasite count (geometric mean, 95 % CI) No./µL 35,011 (28,613–42,839) 36,779 (26,809–50,446) 33,982 (26,016–44,287)
Gametocytaemia on day 0 n/N (%) 10/114 (8.8) 9/43 (20.9) 1/71 (1.4)
Mixed infection n/N (%) 13/114 (11.4) 8/43 (18.6) 5/71 (7.1)
Haematocrit % 37 (32–42) 38 (33–42) 37 (32–42)
Fever on admission n/N (%) 37/114 (32.4) 12/43 (27.9) 25/71 (35.2)
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Discussion
In this study conducted in Northern and Central Myan-
mar DHA-piperaquine was highly efficacious, despite 
the presence of artemisinin resistance, with an overall 
day 3 positivity rate of 18 % (30 % in Myitkyina) [29]. The 
study protocol was designed specifically to assess pro-
longation of parasite clearance half-lives, the hallmark 
of artemisinin resistance in P. falciparum [29]. Para-
site clearance half-life is less prone to confounding by 
baseline parasitaemia than day 3 parasite positivity [28, 
30, 31], and remains the gold-standard for determining 
resistance phenotypes needed for the characterization of 
artemisinin resistance [10, 32–34]. The use of clearance 
half-life to define artemisinin resistance was validated in 
western Cambodia, where a dichotomous distribution 
of half-lives is evident and a 5-h cut-off provides satis-
factory discrimination [30]. At the Myanmar-Thailand 
border where longitudinal studies have been undertaken 
for more than two decades, the C580Y mutation only 
recently replaced earlier K13 mutations associated with 
lesser effects on parasite clearance [2, 35].
Consistent with previous data from the Myanmar-
China border and molecular surveys [1, 4, 5], F446I was 
the predominant k13 mutation in this study. This muta-
tion is associated with a significant slowing in parasite 
clearance, but these data indicate that this does not occur 
to the same extent as that associated with the muta-
tions prevalent further east. The median parasite clear-
ance half-life of F446I infections in this study was 4.7 h, 
less than that obtained by Huang et  al. [4] in patients 
recruited nearby at the Myanmar–China border (less 
than 100 km from the Myitkyina site). This difference is 
most likely to reflect the more frequent measurement 
of parasitaemia in the current study; the protocol used 
6-hourly assessment of parasitaemia in order to capture 
the lag phase of clearance and avoid systematic overesti-
mation of slope half-life [26, 28]. Other factors might also 
Fig. 2 Distribution of parasite clearance half-lives by a geographical 
region b Pf K13 sequence. Solid symbols are from the current study, 
the diamond represents data from Huang et al. [4] and hollow circles 
are from Ashley et al. [2]. Red circles represent parasites with K13 
propeller mutations, blue triangles represent wild-type. Median and 
IQR are shown
Table 2 Clinical and parasitological responses
ACPR adequate clinical and parasitological response
* Chi square statistics
** Mann–Whitney test
Study site Total Myitkyina Thabeikkyin P value
Median time of fever clearance (IQR), hours 6 (6–12) 6 (6–6) 12 (6–18) 0.008**
Median parasite clearance Half-life (IQR), hours 3.3 (2.1–4.8) 4.4 (3.4–6.7) 2.6 (2.0–3.8) <0.0001**
Parasite clearance time (Median, IQR), hours 42 (30–72) 72 (42–96) 36 (24–72) <0.0001**
Parasite clearance Half-life >4 h, n/N (%) 42/114 (37.7) 27/43 (62.8) 16/71 (22.5) P < 0.001*
Parasite clearance half-life >5 h, n/N (%) 26/114 (22.8) 17/43 (39.5) 9/71 (12.7) P < 0.01*
Day 3 parasitaemia, n/N (%) 20/114 (17.5) 13/43 (30.2) 7/71 (9.9) P < 0.01*
Gametocyte carriage time (median, IQR), hours 18 (9–57) 57 (6–81) 16.5 (12–24) 0.31
ACPR on day 42, % (95 % CI) 100 (97–100) 100 (92–100) 100 (95–100)
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have contributed to the differences, including host effects 
(fever, haematocrit, immune status and genetics [36]), 
drug factors, accuracy of microscopic assessment and 
stochastic effects due to sample size.
Until recently, there has been uncertainty with respect 
to the degree of artemisinin resistance in Northern 
Myanmar. The association of F446I, the prevalent k13 
mutation in the region, with an intermediate artemisinin 
resistance phenotype is consistent with clinical and labo-
ratory studies undertaken at the Myanmar–China border. 
Several publications have documented relatively low day 
3 parasite positivity rates in clinical studies from Yingji-
ang County, Yunnan Province [4, 20], where frequencies 
of the F446I mutation are generally 40–60  % [4, 5, 22]. 
For example, in the series of therapeutic efficacy stud-
ies from Yingjiang county described by Huang et al. [4], 
day 3 positivity rate was approximately 12  % while k13 
propeller mutation prevalence was 56  % (mostly F446I 
mutants). Most infections carrying k13 propeller mutants 
were cleared by microscopy by day 3, suggesting the pres-
ence of a ‘milder’ resistance phenotype than observed in 
the TRAC (Tracking Resistance to Artemisinin) study 
(centred on western Cambodia) where most patients car-
rying k13 mutations remained parasite positive at day 
3 [2]. Two recently published studies from the China–
Myanmar border have examined ring-stage survival in 
F446I parasites but these come to different conclusions 
with respect to the phenotypic effect [22, 37]. Overall, the 
F446I mutation prevalence has clearly risen over time at 
the Myanmar–China border [4, 5, 38], suggesting pref-
erential survival after treatment compared to wild-type 
parasites, and thus selection.
In this study, site was also significantly associated with 
delayed parasite clearance (day 3 positivity and prolonged 
half-life), independent of k13 mutations. Most probably, 
this could be a stochastic effect with long half-life infec-
tions simply representing the top end of the log-normal 
distribution of parasite half lives observed with k13 wild-
type infections [30]. This could also reflect host effects 
although an interesting, while an interesting although 
unlikely possibility is that artemisinin resistance might be 
mediated through an alternative (non-k13) mechanism. 
K13 wild-type infections remaining positive at day 3 have 
been found in other parts of Myanmar [39]. Genome-
wide studies of parasite polymorphism will allow study 
of the population structure of F446I mutant parasites and 
determine whether underlying ‘backbone’ mutations play 
a role [32].
What is the future for DHA-piperaquine in Myanmar? 
At present, it remains a highly efficacious and well-toler-
ated treatment for falciparum malaria in Upper Myan-
mar, but if artemisinin resistance worsens, then increasing 
reliance will be placed on the piperaquine component. 
Worsening partner drug resistance has rapidly followed 







Wild type 81 (71.1) 22 (51.2) 59 (83.1)
P443S 1 1 –
F446I 29 18 11
G538 V 1 – 1
P574L 1 1 –
A676D 1 1 –
All K13 propeller mutations 33 (28.9) 21 (48.8) 12 (16.9)
Table 4 Multivariable analysis examining relationship 
between clearance half-life or day 3 positivity and covari-







Half-life cutoff 4 h
 Site (Myitkyina) 4.1 1.7–10.1 0.002
 Kelch 13 (>440) 5.0 1.9–12.9 0.001
Half-life cutoff 5 h
 Site (Myitkyina) 3.5 1.3–9.4 0.01
 Kelch 13 (>440) 2.3 0.9–6.1 0.1
Day 3 positivity
 Parasitaemia on admission 
(>1 % parasitaemia)
4.0 1.2–11.4 0.02
 Site (Myitkyina) 3.2 1.1–9.6 0.04
 Kelch 13 (>440) 2.0 0.7–4.0 0.68
Fig. 3 Mean (95 % CI) change in haematocrit compared with admis-
sion value during 42 day follow up
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emergence of artemisinin resistance at both the Thai–
Myanmar border [17] and in Cambodia, where pipe-
raquine resistance has now emerged and DP failure rates 
have risen alarmingly in the last 2 years [14, 15, 40, 41].
The median (IQR) gametocyte carriage time in this 
study was 18 (9–57) h, significantly less than that in the 
TRAC study [160 (<6–252) h] where primaquine was 
not used [2]. Hence the addition of a single low dose of 
primaquine (0.25 mg/kg) resulted in low rates of gameto-
cyte carriage and was well tolerated, with rapid haemato-
logical recovery from malarial anaemia. G6PD deficiency 
gene frequencies in Myanmar typically range from 10 to 
20 %, so it is likely that G6PD-deficient male patients in 
this study were exposed to primaquine, but without sig-
nificant haemolysis. This is in keeping with recent large-
scale deployments in mass treatment where no serious 
adverse effects have been observed. Related to this, the 
patient population in Myitkina was predominantly young 
men (typically acquiring malaria because of military or 
mining activities in forested areas), an issue that would 
need to be taken into account in any systematic treat-
ment programme.
In summary, this study shows that while treatment effi-
cacy remains high with DHA-piperaquine, artemisinin 
resistance has emerged and is established in Upper 
Myanmar. However, the main k13 mutation observed, 
k13 F446I, was associated with a clearance half-life of 
slightly under 5 h, suggesting an “intermediate resistance” 
phenotype. The study also emphasizes the clearance half-
life remains the gold-standard in research studies of 
artemisinin resistance and shows the value of frequent 
in vivo sampling of parasitaemia in locations where sus-
ceptibility to artemisinins is previously unknown [26]. 
The sampling schedule (6 hourly for 48 h then daily, until 
two negative slides) is more convenient for patients and 
investigators than that used in the TRAC study [2], but 
performs well [26].
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